Evidence-based analysis of cancer treatment innovations, clinical trial design, and the science shaping modern oncology — written by a GCP-certified CRO team in the field.
The NHS-Galleri trial enrolled over 140,000 people. SYMPLIFY tested 5,461 symptomatic patients. Real-world data now covers 111,000+ tests. Here is what the evidence actually shows — and what it does not yet prove.
Read the full article
A prospective study of 250 patients found visceral adiposity (BRI) and insulin resistance (TyG) independently predicted gastric intestinal metaplasia severity better than BMI. TyG achieved AUC 0.848 for advanced precancerous disease.
Casgevy treats 500+ patients. Base and prime editing enter human trials. An 80-year-old's Grade 4 liver AE halts Intellia's Phase 3. AI designs gene-editing enzymes with no natural counterpart. Fifteen primary sources.
PD-L1 assay fragmentation, liquid vs. tissue biopsy, and single-biomarker vs. CGP — three unresolved controversies examined through 12 primary academic sources with citations for every claim.
NHS-Galleri trial (140,000+), SYMPLIFY (5,461 symptomatic patients), 111,000+ real-world tests — a data-focused review of what multicancer early detection can and cannot do.
KRAS-targeted ddPCR detected ctDNA in 65% of localised PDAC patients vs 17% with standard NGS — and defined three survival-stratified risk groups invisible to conventional liquid biopsy.
A landmark noninferiority trial found 49% of eligible men avoided biopsy while maintaining noninferior detection of clinically significant prostate cancer. Here is what the numbers show.
How upfront biomarker strategy separates trials that show a signal from those that show a real treatment effect — and the statistical cost of getting it wrong.
A deep look at what platform trials actually do better, and what operational and regulatory complexity they introduce — with real-world cost and timelines.
The accumulating data linking metabolic syndrome, insulin resistance, and inflammatory pathways to lymphoma and leukaemia — and the trial design implications.
The regulatory and scientific rationale for pre-specified analysis — and the common protocol gaps that give regulators pause at submission.
What chronic lymphocytic leukaemia and small lymphocytic lymphoma actually mean, what to expect from staging conversations, and what treatment options look like.
Screening, consent, visits, and rights — everything you need to know before saying yes to a trial, in plain language without the jargon.
Peer-reviewed articles, GCP guides, and biomarker science resources — written for PIs, CRAs, oncologists, and trial coordinators.